Impact of the presence of CTMCs in blood on the outcome of patients with mastocytosis. (A) PFS and (B) OS for the whole cohort of patients with mastocytosis (n = 193). (C) The impact of the presence of CTMCs on PFS of patients with nonadvanced SM (n = 155). NR, not reached.